25 Leading India Pharmas Spend Less Than Half Global Average On R&D
This article was originally published in PharmAsia News
India drug makers still trail the global average in spending on research and development as a percentage of total sales and even then record a low success rate in innovation attempts.
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.